Battle Over Cardiologist Non-Competes; Declines Well Before CVD; GLP-1s and Stroke

In upstate New York, patients risk losing care as Ellis Medicine and St. Peter’s Health Partners battle in court over the non-compete agreements of 27 cardiologists. (CBS6)

American guidelines were updated regarding perioperative cardiovascular management for noncardiac surgery, with a strong recommendation to discontinue SGLT-2 inhibitors 3 to 4 days prior. (Circulation)

For stroke patients, the benefit of intra-arterial tenecteplase following successful endovascular thrombectomy was sustained out to 12 months, according to a secondary analysis of ANGEL-TNK. (JAMA)

An imaging biomarker of microvascular impairment was linked to the no-reflow phenomenon despite excellent macrovascular reperfusion from stroke thrombectomy. (Stroke)

Functional decline is apparent as early as a decade before a cardiovascular disease (CVD) event, indicating a prolonged window for early identification of higher-risk individuals, according to a nested case-control study. (JAMA Cardiology)

A phase II trial produced promising safety and efficacy data for investigational tipelukast as a treatment for hypertriglyceridemia and metabolic dysfunction-associated steatotic liver disease associated with type 2 diabetes, MediciNova announced.

Microbiome-targeted interventions had modest associations with improved cardiometabolic markers in childhood, a meta-analysis showed. (European Journal of Preventive Cardiology)

For hypotensive critically ill children, adoption of a permissive mean arterial pressure target, potentially reducing exposure to vasoactive drugs, did not improve outcomes in a randomized trial. (JAMA)

Transcatheter tricuspid valve interventions increasingly entered real-world practice by the end of 2025, with treated patients generally similar to pivotal trial populations and the procedures resulting in acceptable outcomes. (JACC: Advances)

GLP-1 drugs were associated with a reduced stroke risk in people with type 2 diabetes, while SGLT-2 inhibitors and DPP-4 inhibitors showed neutral effects, a Swedish nationwide study found. (eClinicalMedicine)

Tempus AI said it got FDA clearance for its ECG-MR artificial intelligence-powered software, which mines standard 12-lead ECGs for signs of mitral regurgitation.

More heart failure clinics are needed in the South and Appalachia, according to a report from the Heart Failure Society of America.

A study validated HEARTBiT as a transcriptomic biomarker for detecting moderate-to-severe acute cellular rejection after heart transplantation. (European Heart Journal)

Drones provided people with out-of-hospital cardiac arrest faster access to automated external defibrillators, especially in areas with high road traffic, according to a French study at the European Emergency Medicine Congress.